PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10556832

Elastase and metalloproteinase activities regulate soluble complement receptor 1 release.

S Sadallah·C Hess·S Miot·O Spertini·H Lutz·J A Schifferli
View original source ↗Export metadata ↓

Abstract

Complement receptor 1 (CR1) is cleaved from the surface of polymorphonuclear cells (PMN) in the membrane-proximal region to yield a soluble fragment (sCR1) that contains the functional domains. The enzymes involved in this cleavage are produced by the PMN itself, since in vitro stimulation of purified PMN is followed by sCR1 release. Purified human neutrophil elastase (HNE) cleaved CR1 from erythrocytes and urinary vesicles originating from podocytes and enhanced tenfold the cleavage of CR1 from activated PMN. The largest fragment released from PMN by HNE was identical in size to CR1 shed spontaneously. The CR1 fragments cleaved from erythrocytes were functional. The shedding of sCR1 by activated PMN was inhibited by phenylmethylsulfonyl fluoride (80 +/- 10%), alpha1-antiprotease (50 +/- 5%) and elafin (60 +/- 5%). Furthermore the cleavage was blocked by the metalloprotease inhibitor 1,10-phenanthroline (70 +/- 6 %) as well as by a monoclonal antibody against human neutrophil collagenase MMP8 (40 +/- 10%). Maximal inhibition of sCR1 shedding was obtained by a combination of 1,10-phenanthroline with elafin (86 +/- 6%). These inhibitors had no effect on L-selectin shedding, indicating that the cleavage of CR1 was specific. In conclusion, elastase or elastase-like activity may be responsible for the shedding of functional sCR1 in vivo, and this activity is controlled by the local release of PMN metalloproteases and alpha1antiprotease.

Explore related subjects

Complement C3bFibrinogenHumansImmunoblottingLeukocyte ElastaseMetalloendopeptidasesNeutrophilsProtease InhibitorsReceptors, ComplementSolubilityJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Sadallah, C Hess, S Miot, O Spertini, H Lutz, J A Schifferli. 1999. Elastase and metalloproteinase activities regulate soluble complement receptor 1 release.. https://doi.org/10.1002/(sici)1521-4141(199911)29%3A11%3C3754%3A%3Aaid-immu3754%3E3.0.co%3B2-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity.

Effective host defense against bacterial invasion is characterized by the vigorous recruitment and activation of inflammatory cells, which is dependent upon the coordinated expression of both pro- and anti-inflammatory cytokines. Interleukin-10 (IL-10) is a recently described cytokine with potent anti-inflammatory properties in vivo and in vitro. In this study we investigated whether IL-10 could directly regulate the ability of neutrophils (PMN) to phagocytose and kill bacteria. Initial studies demonstrated that human recombinant IL-10 (hrIL-10) inhibited the ability of PMN to phagocytose Escherichia coli in vitro. Inhibition of phagocytosis occurred in the absence of changes in CR1 (C3b) or Fc receptor expression, as treatment of PMN with IL-10 failed to induce significant changes in Fc gamma IIR, Fc gamma IIIR or CR1 cell surface expression. However, incubation of PMN with IL-10 resulted in a dose-dependent decrease in CDIIb (Mac-1) expression. In addition to effects on PMN phagocytosis, hrIL-10 significantly attenuated PMN microbicidal activity, as bactericidal assays revealed that co-incubation of PMN with hrIL-10 resulted in a marked decrease in killing of phagocytosed bacteria. Furthermore, IL-10 inhibited the production of superoxide from PMA-stimulated PMN, suggesting that the detrimental effects of IL-10 on PMN microbicidal activity were due, in part, to suppression of respiratory burst. In summary, our studies indicate that IL-10 inhibits PMN-dependent phagocytosis and killing of E. coli in vitro, and suggest that this cytokine may impair effective antibacterial host defense in vivo.

Complement C3b↗
PubMed1994

The role of the carbohydrate chains in complement (C3) fixation by solid-phase-bound human IgA.

In contrast to antigen-antibody complexes containing native human IgA, solid-phase-deposited IgA activates the alternative complement pathway and binds C3b. To investigate the role of carbohydrate chains in this, various human IgA preparations were treated with neuraminidase alone or together with N-glycanase or O-glycanase, or with mixed glycosidases from the oral bacterium, Streptococcus mitis. Depletion of oligosaccharides was determined by carbohydrate analysis. Removal of sialic acid and N-linked glycan chains greatly increased the C3b-fixing properties of normal serum IgA1 and IgA2. Myeloma IgA1 and IgA2 proteins and secretory IgA had higher C3b-binding activity than normal serum IgA, and this was further increased by removal of sialic acid and N-linked glycans. Fc alpha and Fc alpha-SC fragments of myeloma and secretory IgA1, respectively, but not Fab alpha fragments, obtained by cleavage with bacterial IgA1 proteases and also free secretory component, fixed C3b by the alternative pathway.

Complement C3b↗
PubMed1993

Effects of sulphated polyanions on functions of complement factor H.

Heparin and two dextran sulphate preparations with a low or high average molecular mass (M(r) 5000 and 5 x 10(5), respectively) enhanced binding of radioactively labelled complement factor H to the complement protein C3b, coupled to Sepharose 4B, maximally 2.5-4-fold within a polyanion concn range of 12.5-400 micrograms/ml. Despite this, heparin or low molecular mass dextran sulphate had no effect on the activity of H as a cofactor of complement factor I, when C3b bound to Sepharose 4B was used as a substrate, and high molecular mass dextran sulphate inhibited. Heparin or low molecular mass dextran sulphate had also no effect on the decay-accelerating activity of factor H on the alternative pathway C3 convertase, C3b,Bb, and high molecular mass dextran sulphate inhibited this activity, too, regardless of whether Sepharose 4B or sheep erythrocytes were used as carriers of C3b,Bb. These results suggest strongly that fluid phase heparin or dextran sulphate do not inhibit activation of the alternative pathway of complement by augmenting functions of H.

Complement C3b↗